1-6 of 6
Inge Ludwig
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma

Clinical Trials & Observations
F. Smits, Kaz Groen, Mark-David Levin, Claudia Stege, Roel J.W. van Kampen, Ellen van der Spek, Yavuz M. Bilgin, Noortje Thielen, Inger S. Nijhof, Inge Ludwig, Esther G.M. de Waal, Yorick Sandberg, Alain Kentos, Gert-Jan Timmers, Josien C. Regelink, Matthijs Westerman, Koen de Heer, Marie-Christiane MB Vekemans, Nazik Durdu-Rayman, Nicole C.H.P. de Graauw, Maarten R. Seefat, Niels W.C.J. van de Donk, Paula F Ypma, Kazem Nasserinejad, Sonja Zweegman
Journal: Blood
Blood blood.2024025868.
https://doi.org/10.1182/blood.2024025868
Published: 2024
Includes: Supplemental data
Journal Articles

Dynamic Frailty Status Enables Better Prediction of Survival Probability - Results of the HOVON 143 Study

Febe Smits, Kaz Groen, Mark-David Levin, Claudia Stege, Roel JW Van Kampen, Ellen Van Der Spek, Yavuz M Bilgin, Noortje Thielen, Inger S. Nijhof, Inge Ludwig, Esther G.M. De Waal, Yorick Sandberg, Alain Kentos, Gert Jan Timmers, Josien C Regelink, Matthijs Westerman, Koen de Heer, Marie Christiane Vekemans, Nazik Durdu-Rayman, Nicole de Graauw, Maarten R. Seefat, Niels WCJ van de Donk, Paula F Ypma, Kazem Nasserinejad, Sonja Zweegman
Journal: Blood
Blood (2023) 142 (Supplement 1): 342.
https://doi.org/10.1182/blood-2023-180006
Published: 2023
Journal Articles

Exploratory Results of PET-CT and Residual Lymph Node Fine Needle Aspiration of Patients Treated with First-Line Venetoclax and Ibrutinib for CLL/Sll; First Interim Analysis of the Phase 2 HOVON 158/Next STEP Trial

Mark-David Levin, Sabina Kersting, Julie M.N. Dubois, Yvette Norden, Johan A Dobber, Yvonne W.S. Jauw, Anne-Marie van der Kevie-Kersemaekers, Clemens Mellink, Koen de Heer, Leonie van der Burg, Doreen Te Raa, Fransien de Boer, Jolanda Droogendijk, Cecile Idink, Marten R. Nijziel, Lidwine W. Tick, Inge Ludwig, Matthijs Silbermann, Aart Beeker, Mar Bellido, Ludo M. Evers, Gerben JC Zwezerijnen, Carsten U Niemann, Arnon P. Kater
Journal: Blood
Blood (2022) 140 (Supplement 1): 4137–4139.
https://doi.org/10.1182/blood-2022-163209
Published: 2022
Journal Articles

Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study

Kaz Groen, Claudia A.M. Stege, Kazem Nasserinejad, Koen de Heer, Roel J.W. Van Kampen, Maria B.L. Leijs, Noortje Thielen, Matthijs Westerman, Ka Lung Wu, Inge Ludwig, Djamila Issa, Gerjo A. Velders, Marie-Christiane Vekemans, Niels W.C.J. van de Donk, Gert-Jan Timmers, Pieter Sonneveld, Maarten R. Seefat, Fransien Croon-de Boer, Lidwine W. Tick, Ellen van der Spek, Esther G.M. De Waal, Maaike Sohne, Paula F Ypma, Inger S. Nijhof, Saskia K. Klein, Mark-David Levin, Sonja Zweegman
Journal: Blood
Blood (2021) 138 (Supplement 1): 80.
https://doi.org/10.1182/blood-2021-152112
Published: 2021
Journal Articles

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study

Claudia A.M. Stege, MD, Kazem Nasserinejad, Ellen van der Spek, MD PhD, Roel J.W. Van Kampen, MD PhD, Maaike Sohne, MD, Noortje Thielen, MD PhD, Yavuz Bilgin, MD PhD, Esther G.M. De Waal, MD, Inge Ludwig, MD MSc, Maria B.L. Leijs, MD, Alain Kentos, MD, Gert Jan Timmers, MD PhD, Koen de Heer, MD, Matthijs Westerman, MD, Marie Christiane Vekemans, Nazik Durdu-Rayman, MD, Nicole C.H.P. van der Burg-de Graauw, MD, Niels W. C. J. Van De Donk, MD PhD, Pieter Sonneveld, Saskia K. Klein, MD PhD, Mark-David Levin, MD PhD, Sonja Zweegman, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 695.
https://doi.org/10.1182/blood-2019-121694
Published: 2019
Journal Articles

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (IDd) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; First Interim Safety Analysis of the Phase II HOVON 143 Study

Claudia A.M. Stege, MD, Kazem Nasserinejad, PhD, Mark-David Levin, MDPhD, Noortje Thielen, MD PhD, Saskia K. Klein, MD PhD, Inge Ludwig, MD MSc, Matthijs Westerman, MD, Paula F Ypma, MDPhD, Yavuz Bilgin, MDPhD, Maaike Sohne, MD, Esther de Waal, PhD, Niels WCJ van de Donk, MD PhD, Pieter Sonneveld, MDPhD, Sonja Zweegman, MDPhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 596.
https://doi.org/10.1182/blood-2018-99-114668
Published: 2018